SCHEMBL21808306

SCHEMBL21808306

C[C@@H]1CN(C(=O)O)C[C@H](C)N1c1ncc2[nH]nc(-c3ccc(C4CCN(CCO)C4)cc3)c2n1

nearest known ligand 0.85

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ FGFR2 P21802 16/20 0.85
▸ FGFR3 P22607 15/20 0.85
▸ FGFR1 P11362 14/20 0.85
▸ ACVR1 Q04771 13/20 0.71
▸ BMPR1A P36894 5/20 0.57
▸ TGFBR1 P36897 5/20 0.57
▸ ACVRL1 P37023 5/20 0.57
▸ HAMP P81172 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30434082 1.00 FGFR2 (0.85) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL30432665 0.92 FGFR2 (1.00) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21846764 0.92 FGFR2 (1.00) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21808591 0.90 ACVR1 (0.83) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL30434492 0.90 ACVR1 (0.83) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL30767268 0.88 FGFR2 (0.77) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21846707 0.83 ACVR1 (1.00) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21808525 0.80 FGFR2 (0.82) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21808276 0.79 FGFR2 (0.83) FGFR2FGFR3FGFR1ACVR1BMPR1A
SCHEMBL21808502 0.79 FGFR2 (0.83) FGFR2FGFR3FGFR1ACVR1BMPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 — — EP claimed
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-09-07 — — US claimed
EP-3856348-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS Incyte Corporation (US) 2021-08-04 — — EP claimed
WO-2020068729-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS INCYTE CORPORATION (US) 2020-04-02 — — WO claimed
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-26 — — US claimed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 — — EP disclosed
US-20220017521-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-01-20 — — US disclosed
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2021-09-07 — — US disclosed
EP-3856348-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS Incyte Corporation (US) 2021-08-04 — — EP disclosed
WO-2020068729-A1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 ABD/OR FGFR MODULATORS INCYTE CORPORATION (US) 2020-04-02 — — WO disclosed
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095250-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF ALK, FGFR1, FGFR2 FGFR2 3/4885FGFR3 4/4885FGFR1 2/4885
US-20220017521-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF ALK, FGFR1, FGFR2 FGFR2 3/4885FGFR3 4/4885FGFR1 2/4885
US-11111247-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 FGFR2 3/4885FGFR3 4/4885FGFR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback